First Department of Internal Medicine (Division of Hematology), Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Int J Hematol. 2010 Jan;91(1):128-31. doi: 10.1007/s12185-009-0466-3. Epub 2010 Jan 5.
We report a case of imatinib- and nilotinib-resistant Ph-positive chronic myeloid leukemia (CML) in blast crisis in which successful pretreatment with dasatinib with cord blood transplantation resulted in molecular remission. Before dasatinib therapy, the patient was found to have a F359V BCR-ABL mutation. He was treated with dasatinib for just 16, 19 days before allogeneic stem cell transplantation. This successful case indicates that reduction of tumor burden by second-generation tyrosine kinase inhibitors, in combination with stem cell transplantation, might be effective to treat CML, even in the advanced phase.
我们报告了一例伊马替尼和尼洛替尼耐药的费城染色体阳性慢性髓性白血病（CML）急变期病例，该患者在接受达沙替尼预处理和脐带血移植后获得了分子缓解。在达沙替尼治疗前，该患者被发现存在 F359V BCR-ABL 突变。在进行异基因干细胞移植前，他仅接受了 16、19 天的达沙替尼治疗。这个成功的案例表明，第二代酪氨酸激酶抑制剂降低肿瘤负担，联合干细胞移植，可能对治疗 CML 有效，即使在晚期也是如此。
